



Representative Legal Matters

Piotr (Pete) E. Korzynski

Since joining the Firm, Pete has worked on the following selected matters, representing:

- Servier, an independent international pharmaceutical group, in its all-cash USD 2.5 billion acquisition of Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on developing targeted therapies for pediatric cancers and other cancers with high unmet medical needs.
- H. Lundbeck A/S, a global pharmaceutical company focused on treatments for brain diseases, in its acquisitions of:
 - Alder Biopharmaceuticals, Inc., a company focused on migraine treatment and prevention, in a transaction valued at USD 1.95 billion in cash and contingent value rights;
 - Longboard Pharmaceuticals, Inc., a company focused on developing medicines for neurological diseases, in a transaction valued at USD 2.6 billion in cash; and
 - Avadel Pharmaceuticals plc, a biopharmaceutical company focused on sleep disorders and the developer of LUMRYZ, for up to USD 2.4 billion in a combination of cash and contingent value rights through an unsolicited competing proposal that was ultimately not consummated.
- Resulticks Global Companies Pte Limited, a global real-time, AI-driven customer intelligence solutions company, on its all-stock sale to Diginex Limited in a transaction valued at approximately USD 1.5 billion.
- Marel hf., a global food processing company, in its EUR 3.5 billion sale to John Bean Technologies Corporation.
- Numab Therapeutics, a clinical-stage biotech company, in its USD 1.25 billion sale of its "NM26" program assets related to a treatment targeting atopic dermatitis to Johnson & Johnson.
- Olink Holding AB (publ), a global proteomics products and services company, in its USD 3.1 billion sale to Thermo Fisher Scientific.
- Cummins Inc., a global engine and power system manufacturer and distributor, in the global carve-out and USD 316 million IPO split-off of its filtration business through Atmus Filtration Technologies Inc.
- Abbott Laboratories, a global medical device company, in its acquisitions of:
 - Cardiovascular Systems, Inc., a medical device company, for USD 890 million; and
 - GLP systems GmbH, a lab automation company, from Sonic Healthcare and other minority shareholders.
- Bayer AG, a global life sciences company, in its acquisitions of:
 - Asklepios BioPharmaceutical, Inc., a gene therapy company, in a transaction valued at up to USD 4 billion, including potential milestone payments; and

Baker McKenzie.

- Vividion Therapeutics Inc., a pharmaceutical company focused on cancers and inflammatory diseases, in a transaction valued at up to USD 2 billion, including potential milestone payments.
- Zen-Noh Grain Corporation, a grain elevator operating company, in its US DOJ- mandated divestiture of US grain elevators to Viserion Grain LLC to permit its USD 300 million acquisition from Bunge Limited of 35 US grain elevators.
- Acorda Therapeutics, Inc., a biopharmaceutical company focused on developing therapies for neurological disorders, in its USD 185 million sale of substantially all of its assets to Merz Pharma GmbH & Co. KGaA through a sale process pursuant Section 363 of the United States Bankruptcy Code.
- Owensboro Grain Holding Company, Inc., a fifth-generation family owned soybean processing facility and refinery, in its sale to Cargill, Inc.
- Huttig Building Products, Inc., a distributor of millwork, building materials and wood products for residential construction and in-home improvement, in its USD 350 million sale to Woodgrain, Inc.
- Virtual Therapeutics Corporation in its acquisition of Akili, Inc., a digital medicine company.
- LVMH Moët Hennessy Louis Vuitton SE in its acquisition of Belmond Ltd., owner, part- owner or manager of 45 luxury hotel, restaurant, train and river cruise properties, in a transaction with an enterprise value of USD 3.2 billion.
- Archer Daniels Midland Company in its EUR 1.5 billion acquisition of Neovia, a global provider of animal nutrition solutions.
- Donaldson Company, Inc. in its proposed sale of an auto filtration business division to a private equity buyer.
- Indra Sistemas, S.A. in its acquisition of a private company focused on energy transmission software and services.
- Prior to joining the Firm, Pete worked on the following selected matters, representing:
 - Ball Corporation in its USD 8.4 billion acquisition of Rexam PLC and its related antitrust-mandated divestiture of USD 3.42 billion in assets to Ardagh Group S.A.
 - The Hillshire Brands Company in its proposed USD 6.6 billion acquisition of Pinnacle Foods Inc. and subsequent USD 8.55 billion sale in an unsolicited and contested transaction to Tyson Foods, Inc.
 - Wisconsin Energy Corporation in its USD 5.7 billion acquisition of Integrys Energy Group, Inc.
 - Horizon Pharma Public Limited Company in its unsolicited USD 2.26 billion tender offer to acquire Depomed, Inc.
 - Stryker Corporation in its USD 1.65 billion acquisition of MAKO Surgical Corp. and its USD 664 million acquisition of Entellus Medical, Inc.
 - Digital River Inc. in its USD 840 million sale to an investor group led by Siris Capital Partners.
 - Ecolab Inc. in its acquisition of Swisher Hygiene, Inc.
 - Northern Trust Corporation in its offering of USD 750 million in 3.950% subordinated notes due 2025.

Baker McKenzie.

- CF Industries, Inc. in its offering of USD 500 million of 3.400% senior secured notes due 2021 and USD 750 million of 4.500% senior secured notes due 2026.
- Morgan Stanley as the lead underwriter in Hospira, Inc.'s offering of USD 350 million of 5.2% notes due 2020 and USD 350 million of 5.8% notes due 2023.
- Kemper Corporation in its offering of USD 150 million of 7.375% subordinated debentures due 2054.